CA-ALATION
Alation Inc. , the leader in enterprise data catalogs, today announced the results of a global study, Leverage Your Data, A Data Strategy Checklist for the Journey to the Data-Driven Enterprise , which found that while nearly every company wants to be data-driven, the lack of documentation and knowledge about data inhibits that goal. The study, sponsored by Alation and carried out by Business Application Research Center (BARC) , reveals that a key enabler to becoming a data-driven enterprise is the implementation of a successful data catalog that drives active contribution and collaboration from the business user.
According to the study, 90% of respondents indicate that data has a high priority in enterprise decision-making yet only 25% state that decisions are predominantly or purely made based on data. Several roadblocks inhibit the business user from embracing data and therefore prevent organizations from becoming data-driven. Participants report a lack of information and documentation on data, insight into who is using what data and for what purpose, and inconsistent meanings and interpretations of data as blockers. They also cite that data access is too complicated and that significant time is wasted asking the same questions about data or repeating work, further preventing business users from making data-driven decisions.
To overcome these obstacles, the report says that enterprises need to foster a data culture that empowers the business users. The data catalog drives data democratization by providing widespread access to data and encouraging a collaborative information exchange where data users – from business users to data analysts – can engage in an iterative process that ensures data quality and the proper use of data. The catalog tackles the challenges associated with data documentation by providing a business glossary that facilitates cross-departmental access to approved data definitions, ensuring that the meaning and interpretations of key figures in the organization are consistent. By removing these hurdles and empowering business users with a collaborative platform, organizations are able to unlock the true value of their data. This is why 77% of respondents currently use or are planning to use a data catalog.
“The BARC study mirrors the challenges our customers experienced prior to using Alation. Organizations need a data catalog that enables search and discovery, provides the context on how to use the data, and fosters collaboration among data users,” said Satyen Sangani, CEO and co-founder of Alation. “Alation is the foundation for building a data culture and we’re seeing more enterprises leverage our data catalog to drive that cultural shift and derive more value from their data.”
For four consecutive years, Alation has been named the top-ranked data catalog in Dresner Advisory Services’ 2020 Wisdom of Crowds® Data Catalog Market Study . Alation has also been recognized as a leader in the Forrester Wave for Machine Learning Data Catalogs , a three-time leader in Gartner’s Magic Quadrant for Metadata Management Solutions , and selected as a Gartner Peer Insights Customer’s Choice for Metadata Management Solutions .
To download a copy of Leverage Your Data, a Data Strategy Checklist for the Journey to the Data-Driven Enterprise , click here .
To learn more about the study, register for the BARC Launch Party: How do Companies Find, Understand and use Trusted Data for Analytics? which is being held twice, once at 9am CEST and once at 5pm CEST on June 25, 2020.
To learn how customers use Alation for data governance, register for our upcoming webinar with Bob Seiner, author of Non-Invasive Data Governance , and Alation customer, Riot Games on July 7, 2020.
About Alation
Alation pioneered the data catalog market, leading the evolution of data management towards driving data culture. Alation customers leverage the data catalog as a platform for data search & discovery, data governance, data stewardship, analytics, and digital transformation. With its powerful Behavioral Analysis Engine, inbuilt collaboration capabilities, and open interfaces, Alation provides a platform to support a broad range of data intelligence solutions by combining machine learning with human insight to tackle the most demanding challenges in data management. Nearly 200 organizations are driving their data cultures and improving their organizations’ decision making with Alation, including AbbVie, DraftKings, Exelon, Finnair, Genentech, GoDaddy, Marks & Spencer, MercadoLibre, Munich Re, New Balance, New Relic, Pfizer, Scandinavian Airlines, Scout24 and US Foods. Headquartered in Silicon Valley, Alation is funded by Costanoa Ventures, Data Collective Venture Capital, Icon Ventures, Sapphire Ventures, and Salesforce Ventures. For more information, visit alation.com .
About BARC
BARC (Business Application Research Center) is one of Europe’s leading analyst firms for business software, focusing on the areas of data, business intelligence (BI) and analytics, enterprise content management (ECM) and customer relationship management (CRM). The company was founded in 1999 as a spin-off of the Chair of Business Administration and Information Systems at the Julius-Maximilians-University in Würzburg. Today, BARC combines empirical and theoretical research, technical expertise and practical experience, including a constant exchange with all market participants. For more information, visit: www.barc-research.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200622005757/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom